Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Phone650-251-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$787.31 million
Profitability
Miscellaneous
Employees2,480
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, April, 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.38. The business earned $202.50 million during the quarter, compared to analysts' expectations of $199.72 million. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. Omnicell's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 EPS. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What guidance has Omnicell issued on next quarter's earnings?
Omnicell issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $2.62-2.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.51. The company issued revenue guidance of $880-900 million, compared to the consensus revenue estimate of $890.22 million.Omnicell also updated its FY 2019 guidance to $2.62-2.82 EPS.
What price target have analysts set for OMCL?
7 equities research analysts have issued 1-year target prices for Omnicell's stock. Their predictions range from $61.00 to $90.00. On average, they expect Omnicell's stock price to reach $80.1429 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
Has Omnicell been receiving favorable news coverage?
News stories about OMCL stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Omnicell earned a news impact score of 0.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Omnicell's key competitors?
What other stocks do shareholders of Omnicell own?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
- Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.72%), Wellington Management Group LLP (7.96%), Conestoga Capital Advisors LLC (3.75%), Dimensional Fund Advisors LP (3.27%), Eagle Asset Management Inc. (2.28%) and Janus Henderson Group PLC (1.72%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.
Which major investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Champlain Investment Partners LLC, Copper Rock Capital Partners LLC, Voya Investment Management LLC, Oak Ridge Investments LLC, Fort Washington Investment Advisors Inc. OH, Goldman Sachs Group Inc. and West Coast Financial LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.
Which major investors are buying Omnicell stock?
OMCL stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, PNC Financial Services Group Inc., JPMorgan Chase & Co., BlackRock Inc., OppenheimerFunds Inc., Carillon Tower Advisers Inc., Redwood Investments LLC and Geode Capital Management LLC. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $79.57.
How big of a company is Omnicell?
Omnicell has a market capitalization of $3.28 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
